DMB-I in the Treatment of Alzheimer Type Dementia

Summary

The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.

Timeline

Start

2023-12-27

Primary completion

2025-01-13

Completion

2025-01-31

Outcome

Met primary endpoint

paper The efficacy of DMB-I at a dose of 60 mg/day was demonstrated by assessing the primary efficacy criterion PMID 42141012 ↗

paper a significant change in the ADAS-cog score after 26 weeks of treatment compared with baseline. PMID 42141012 ↗

Publications

• Gorin BI, Pozdnyakov SO, Potapova KA, Tukhovskaya EA, Gorchakov DS. Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups. Sci Rep. 2026 May 15;16(1):14027. doi: 10.1038/s41598-026-49538-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	10 mg	—
Subject	Latrepirdine	Small molecule	20 mg	—

Indications